Alivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve the Audited Financial ....
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alivus Life Sciences (formerly Glenmark Life Sciences) has intimated BSE and NSE about a Board meeting scheduled for May 14, 2026. The meeting will consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The Board will also consider recommending a dividend on equity shares for FY 2025-26. The company has closed its trading window from April 1, 2026 to May 16, 2026 for designated persons under SEBI's Insider Trading Regulations. This is a routine pre-results announcement intimation and does not contain actual financial figures.
This is a standard regulatory intimation and does not contain any financial results or material information. The actual financial performance and dividend announcement will be known after the Board meeting on May 14, 2026.